^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PPAR γ agonist

    Related drugs:
    5d
    A halogenated pregnenolone analogue suppresses HepG2 proliferation and induces apoptosis via PPARγ regulation. (PubMed, RSC Med Chem)
    Western blots using a PPARγ agonist (pioglitazone) and antagonist (T0070907) validated its crucial role in mediating compound 20-induced apoptosis in HepG2 cells...Furthermore, a CETSA assay provided additional support, confirming that compound 20 enhances PPARγ's thermal stability. Collectively, these findings strongly suggest that compound 20 inhibits HepG2 proliferation and promotes HepG2 apoptosis via PPARγ modulation, positioning it as a promising lead compound for hepatocellular carcinoma treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    11d
    Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells. (PubMed, Ann Hematol)
    This study investigated the impact of adding pioglitazone to imatinib therapy in 26 newly diagnosed chronic-phase CML patients. No abstract available
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1) • CITED2 (Cbp/P300 Interacting Transactivator With Glu/Asp Rich Carboxy-Terminal Domain 2)
    |
    imatinib
    13d
    Effects of tea polyphenols on brain structure and function of hippocampus in aged type 2 diabetes mellitus rats with anxiety and depression-like behavior. (PubMed, Brain Res)
    TP intervention mitigated alterations in brain structure and function as well as anxiety and depression-like behaviors in aged T2DM rats.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • BDNF (Brain Derived Neurotrophic Factor)
    |
    rosiglitazone
    14d
    EPICS-IV: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (clinicaltrials.gov)
    P3, N=89, Not yet recruiting, Zydus Therapeutics Inc.
    New P3 trial
    17d
    Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (clinicaltrials.gov)
    P1, N=30, Recruiting, Zydus Therapeutics Inc. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    18d
    2025-523266-24-00: A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo (2025-523266-24-00)
    P1/2, N=60, Not yet recruiting, I.F.O. Istituti Fisioterapici Ospitalieri
    New P1/2 trial
    18d
    Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets (clinicaltrials.gov)
    P=N/A, N=24, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New trial
    18d
    337HVPK24018: A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor (2025-524385-18-00)
    P1, N=30, Recruiting, Inventiva
    New P1 trial
    26d
    The novel SPPARM YR3-16 ameliorates metabolic disorders in vivo and attenuates adipocyte inflammation in vitro via PPARγ-dependent ERK suppression. (PubMed, Int Immunopharmacol)
    YR3-16 is a novel tetrahydroisoquinoline derivative that selectively activates PPARγ and exhibits a binding mode distinct from that of pioglitazone...In 3 T3-L1 adipocytes, YR3-16 (10 μM) reprogrammed lipid metabolism at the gene transcriptional level, and suppressed pro-inflammatory cytokine secretion (tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β)), associated with the inhibition of extracellular signal-regulated kinase (ERK) signaling pathway, which was abolished by the peroxisome proliferator-activated receptor γ antagonist GW9662. YR3-16, as a novel SPPARM, concurrently improves metabolic disorders in vivo and attenuates adipocyte inflammation via peroxisome proliferator-activated receptor γ activation, highlighting its potential for treating obesity-related diseases.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • IL1B (Interleukin 1, beta)
    1m
    Study on the Characteristics and Cellular Origins of the Sebaceous Gland (ChiCTR2500114709)
    P4, N=20, Not yet recruiting, WUHAN UNIVERSITY; WUHAN UNIVERSITY
    New P4 trial
    |
    rosiglitazone
    1m
    Insulin Regulation of Lipolysis and Lipolysis Proteins (clinicaltrials.gov)
    P1, N=64, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    G0S2 (G0/G1 Switch 2)
    1m
    Repurposing Rosiglitazone Induces Apoptosis Accompanied by Impaired Antioxidant Defense in Cholangiocarcinoma Cells: Findings from Proteomic and Functional Analyses. (PubMed, Pharmaceuticals (Basel))
    Its apoptosis-inducing effect is independent of PPARγ activation. These findings underscore the therapeutic potential of RSG for CCA treatment.
    Journal
    |
    CASP3 (Caspase 3) • ANXA1 (Annexin A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CASP7 (Caspase 7)
    |
    rosiglitazone